Facebook
Twitter
Telegram
Report an ErrorTarsus Pharmaceuticals Balance Sheet 2011-2024 | TARS
Annual Balance Sheet Tarsus Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-195 M | -51.5 M | -170 M | -168 M | -57.8 M | -2.36 M | - | - | - | - | - | - | - |
Long Term Debt |
29.8 M | 19.4 M | 585 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
398 K | 721 K | 609 K | 282 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 605 K | 63.5 M | 3.56 M | - | - | - | - | - | - | - |
Total Current Liabilities |
36.9 M | 15.4 M | 11.5 M | 5.39 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
68.5 M | 35 M | 12.2 M | 5.99 M | 64.3 M | 3.74 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 697 K | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-245 M | -109 M | -46.7 M | - | -6.03 M | -1.36 M | - | - | - | - | - | - | - |
Total Assets |
265 M | 228 M | 179 M | 172 M | 58.3 M | 2.39 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
225 M | 71.7 M | 171 M | 168 M | 58 M | - | - | - | - | - | - | - | - |
Book Value |
197 M | 193 M | 167 M | 166 M | -6 M | -1.35 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
197 M | 193 M | 167 M | 166 M | -6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Tarsus Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
29.9 M | 29.8 M | 29.7 M | 24.6 M | 24.5 M | 19.4 M | 19.4 M | 19.3 M | 19.2 M | - | 755 K | 405 K | 456 K | 549 K | 549 K | 549 K | 549 K | 100 K | 100 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
74.1 M | 68.5 M | 54.7 M | 41.2 M | 37.8 M | 35 M | 33.8 M | 31.3 M | 32.3 M | 12.2 M | 11.3 M | 11 M | 10.7 M | 5.99 M | 5.99 M | 5.99 M | 5.99 M | 919 K | 919 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 174 K | 697 K | 1.03 M | 1.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-280 M | -245 M | -203 M | -164 M | -132 M | -109 M | -95.2 M | -72.7 M | -66.9 M | -46.7 M | -31.8 M | -16.1 M | -22.5 M | -32.8 M | -32.8 M | -32.8 M | -32.8 M | -6.03 M | -6.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
349 M | 265 M | 268 M | 189 M | 211 M | 228 M | 236 M | 253 M | 181 M | 179 M | 190 M | 203 M | 194 M | 172 M | 172 M | 172 M | 172 M | 58.3 M | 58.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
194 M | 225 M | 227 M | 107 M | 66 M | 71.7 M | 169 M | 245 M | 175 M | 171 M | 184 M | 177 M | 156 M | 168 M | 168 M | 168 M | 168 M | 58 M | 58 M | - | - | 2.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
275 M | 197 M | 214 M | 148 M | 173 M | 193 M | 203 M | 222 M | 149 M | 167 M | 179 M | 192 M | 183 M | 166 M | 166 M | 166 M | 166 M | 57.4 M | 57.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
275 M | 197 M | 214 M | 148 M | 173 M | 193 M | 203 M | 222 M | 149 M | 167 M | 179 M | 192 M | 183 M | 166 M | 166 M | 166 M | 166 M | -6 M | -6 M | -3.92 M | -3.1 M | -1.35 M | - | - | - | -44 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency